SCHEMBL13100599

SCHEMBL13100599

Cc1ccc(/C=C/c2ccc(N=O)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 4/20 0.52
PTGS2 P35354 4/20 0.50
PTGS1 P23219 3/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
ALOX5 P09917 1/20 0.50
RELA Q04206 1/20 0.48
FGF23 Q9GZV9 3/20 0.47
CYP2A6 P11509 1/20 0.46
FBP1 P09467 1/20 0.45
CA12 O43570 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
ALDH1A1 P00352 2/20 0.44
MAPT P10636 1/20 0.44
CA1 P00915 1/20 0.43
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL941642 0.85
SCHEMBL11244353 0.85 ALDH1A1 (0.52) PTGS2PTGS1NPC1RAB9ASMN1; SMN2
SCHEMBL28162394 0.83 ALDH1A1 (0.65) PTGS2PTGS1NPC1RAB9ASMN1; SMN2
SCHEMBL18427609 0.82 RAB9A (0.57) NFE2L2PTGS2NPC1RAB9ASMN1; SMN2
SCHEMBL16547155 0.81 NFE2L2 (0.56) NFE2L2PTGS2PTGS1NPC1RAB9A
SCHEMBL318786 0.80 NFE2L2 (0.74) NFE2L2PTGS2PTGS1NPC1RAB9A
(E)-1,2-Di-P-Tolylethene SCHEMBL1305582 0.80 NFE2L2 (0.74) NFE2L2PTGS2PTGS1NPC1RAB9A
(E)-1,2-Di-P-Tolylethene SCHEMBL1793692 0.80 NFE2L2 (0.74) NFE2L2PTGS2PTGS1NPC1RAB9A
(E)-1,2-Di-P-Tolylethene SCHEMBL1305580 0.80 NFE2L2 (0.74) NFE2L2PTGS2PTGS1NPC1RAB9A
SCHEMBL318785 0.80 NFE2L2 (0.74) NFE2L2PTGS2PTGS1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100266500-A1 STILBENE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100266500-A1 STILBENE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES APP, APBA1, PSEN1 NFE2L2 2543/4885PTGS2 3442/4885PTGS1 3373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.